{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T06:10:30Z","timestamp":1685081430523},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s11739-009-0290-z","type":"journal-article","created":{"date-parts":[[2009,7,31]],"date-time":"2009-07-31T07:50:23Z","timestamp":1249026623000},"page":"485-490","source":"Crossref","is-referenced-by-count":2,"title":["Leukocyte interferon-\u03b1 and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon"],"prefix":"10.1007","volume":"4","author":[{"given":"Luigi E.","family":"Adinolfi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Durante-Mangoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Salzillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo","family":"Marrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Francoise","family":"Tripodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano","family":"Restivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonietta","family":"Merola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Zampino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,1]]},"reference":[{"key":"290_CR1","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMct061675","volume":"355","author":"JH Hoofnagle","year":"2006","unstructured":"Hoofnagle JH, Seef LB (2006) Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 355:2444\u20132451","journal-title":"N Engl J Med"},{"key":"290_CR2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958\u2013965","journal-title":"Lancet"},{"key":"290_CR3","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffmann ML, Reddy KR et al (2002) Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 347:975\u2013982","journal-title":"N Engl J Med"},{"key":"290_CR4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette H Jr, Morgan TR et al (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346\u2013355","journal-title":"Ann Intern Med"},{"key":"290_CR5","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","volume":"123","author":"JG McHutchison","year":"2002","unstructured":"McHutchison JG, Manns M, Patel K et al (2002) Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123:1061\u20131069","journal-title":"Gastroenterology"},{"key":"290_CR6","doi-asserted-by":"crossref","first-page":"s237","DOI":"10.1002\/hep.1840360730","volume":"36","author":"MW Fried","year":"2002","unstructured":"Fried MW (2002) Side effects of therapy for hepatitis C and their management. Hepatology 36:s237\u2013s244","journal-title":"Hepatology"},{"key":"290_CR7","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0016-5085(03)00394-9","volume":"124","author":"MW Russo","year":"2003","unstructured":"Russo MW, Fried MW (2003) Side effects of therapy for chronic hepatitis C. Gastroenterology 124:1711\u20131719","journal-title":"Gastroenterology"},{"key":"290_CR8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2893.1998.00113.x","volume":"5","author":"B Cacopardo","year":"1998","unstructured":"Cacopardo B, Benanti F, Brancati G et al (1998) Leucocyte IFN-alpha retreatment for chronic hepatitis C patients previously intolerant to other interferons. J Viral Hepat 5:333\u2013539","journal-title":"J Viral Hepat"},{"key":"290_CR9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00063030-200317030-00006","volume":"17","author":"S Tripi","year":"2003","unstructured":"Tripi S, Soresi M, Di Gaetano G et al (2003) Leucocyte interferon-alpha for patients with chronic hepatitis C intolerant to other alpha interferons. BioDrugs 17:201\u2013205","journal-title":"BioDrugs"},{"key":"290_CR10","first-page":"159","volume":"14","author":"C Cagnoni","year":"1999","unstructured":"Cagnoni C, Pancotti D, Carrara G (1999) The retreatment with natural leukocyte interferon alfa-n3 of chronic hepatitis C patients: the intolerant and nonresponsive results to prior treatment with recombinant alfa interferon. Ann Ital Med Int 14:159\u2013165","journal-title":"Ann Ital Med Int"},{"key":"290_CR11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1013798812144","volume":"47","author":"L Dughera","year":"2002","unstructured":"Dughera L, Battaglia E, Serra AM et al (2002) Human leukocytes interferon-alpha treatment for chronic HCV-related hepatitis in hemophilic patients previously intolerant to other interferons-alpha. Dig Dis Sci 47:427\u2013431","journal-title":"Dig Dis Sci"},{"key":"290_CR12","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/01.TP.0000055834.67634.74","volume":"75","author":"S Fagiuli","year":"2003","unstructured":"Fagiuli S, Pevere S, Minniti F et al (2003) Natural leukocyte interferon alpha for treatment of chronic viral hepatitis in heart transplant recipients. Transplantation 75:982\u2013986","journal-title":"Transplantation"},{"key":"290_CR13","first-page":"199","volume":"47","author":"G Cagnoni","year":"2000","unstructured":"Cagnoni G, Pancotto D, Carrara G (2000) Management of patients with HCV infection poorly tolerant to recombinant interferon alpha. Hepatogastroenterology 47:199\u2013203","journal-title":"Hepatogastroenterology"},{"key":"290_CR14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1742-1241.2003.tb11390.x","volume":"57","author":"A Benci","year":"2003","unstructured":"Benci A, Caremani M, Tacconi D (2003) Thrombocytopenia in patients with HCV-positive chronic hepatitis: efficacy of leukocyte interferon alpha treatment. Int J Clin Pract 57:16\u201319","journal-title":"Int J Clin Pract"},{"key":"290_CR15","unstructured":"AISF (2009) Hot topics in hepatitis C virus treatment: recommendations from an AISF\/SIMIT\/SIMAST expert opinion meeting, Naples, June 2008. AISF online. www.webaisf.org"},{"key":"290_CR16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1365-2893.1998.00103.x","volume":"5","author":"GR Foster","year":"1998","unstructured":"Foster GR, Finter NB (1998) Are all type I human interferons equivalent? J Viral Hepat 5:143\u2013152","journal-title":"J Viral Hepat"},{"key":"290_CR17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/1097-0282(2000)55:4<254::AID-BIP1001>3.0.CO;2-1","volume":"55","author":"S Pestka","year":"2000","unstructured":"Pestka S (2000) The human interferon alpha species and receptors. Biopolymers 55:254\u2013287","journal-title":"Biopolymers"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-009-0290-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-009-0290-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-009-0290-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T05:56:06Z","timestamp":1685080566000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-009-0290-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,1]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["290"],"URL":"https:\/\/doi.org\/10.1007\/s11739-009-0290-z","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,1]]}}}